Summit Therapeutics is trading at $13.54, down 10.2% from a comparison close of $15.07 during regular trading. This is a price-action follow-up, so a separate catalyst may not be included.
🔴 Summit Therapeutics is trading 10.2% down
Summit Therapeutics PLC
Related News
SMMT
Summit Starts Phase II/III Trial of Ivonescimab for First-Line Biliary Cancer
SMMT
🔴 Summit Therapeutics is trading 5% down in pre-market amid S&P 500 and Nasdaq declines
SMMT
Summit Therapeutics Proposes Doubling Authorized Shares to Support Preferred Conversion
SMMT
🟢 Summit Therapeutics is trading 5% up today amid broader market rebound
SMMT